Table 6 Univariable analysis of breast cancer-specific survival
Variable | Whole study cohort (n = 61) | ER-positive patients (n = 50) | ||||||
|---|---|---|---|---|---|---|---|---|
Event/at risk (% survival) | Log rank P | HRa | 95% CI | Event/at risk (% survival) | Log rank P | HRa | 95% CI | |
Pre-operative randomization | ||||||||
Fasting | 1/35 (97) | 1 | 0/29 (100) | 1 | ||||
Carbohydrates | 4/26 (85) | 0.086 | 4.4 | 0.88 to 21.7 | 4/21 (81) | 0.015 | a | a |
Nodal status | ||||||||
N0 | 1/43 (98) | 1/33 (82) | 1 | |||||
N+ | 4/18 (78) | 0.012 | 4.4 | 1.05 to 18.5 | 3/17 (82) | 0.080 | 2.80 | 0.63 to 12.6 |
Tumor size | – | – | ||||||
T1 | 0/45 (100) | 1 | 0/40 (100) | 1 | ||||
T2 | 5/16 (69) | < 0.0001 | 5.5 | 1.32 to 23.1 | 4/10 (60) | < 0.0001 | a | a |
Nottingham grade b | 0.556 | 0.352 | ||||||
Grade 1 | 0/11 (100) | 1 | 0/11 (100) | 1 | ||||
Grade 2 | 3/30 (90) | a | a | 3/30 (90) | a | a | ||
Grade 3 | 2/20 (90) | a | a | 1/9 (89) | a | a | ||
Estrogen receptor | – | – | – | – | ||||
Positive (≥ 1%) | 4/50 (92) | 1 | – | – | – | – | ||
Negative (< 1%) | 1/11 (91) | 0.852 | 0.64 | 0.079 to 5.21 | – | – | – | – |
Progesterone receptor | ||||||||
Positive (≥10%) | 4/41 (90) | 1 | 3/37 (92) | 1 | ||||
Negative (< 10%) | 1/20 (95) | 0.543 | 0.51 | 0.057 to 4.59 | 1/13 (92) | 0.94 | 0.93 | 0.1 to 8.9 |
HER2 | ||||||||
Negative (0 to 1+) | 4/57 (93) | 1 | 3/49 (94) | 1 | ||||
Positive (2+ to 3+) | 1/4 (75) | 0.248 | 3.37 | 0.38 to 30.2 | 1/1 (0) | 0.001 | 11.7 | 1.31 to 105.1 |
MAI | ||||||||
< 10 | 3/41 (93) | 1 | 3/39 (92) | 1 | ||||
≥ 10 | 2/19 (90) | 0.645 | 1.5 | 0.25 to 9.1 | 2/10 (80) | 0.23 | 4.1 | 0.6 to 29.3 |
MAI | ||||||||
< 3 | 1/16 (94) | 1 | 1/16 (88) | 1 | ||||
≥ 3 | 4/44 (91) | 0.735 | 1.46 | 0.16 to 13.0 | 3/33 (85) | 0.76 | 1.4 | 0.15 to 13.8 |
PPH3 | ||||||||
< 13 | 2/35 (94) | 1 | 2/35 (94) | 1 | ||||
> 13 | 3/26 (89) | 0.426 | 2.0 | 0.34 to 12.2 | 2/15 (87) | 0.40 | 2.3 | 0.32 to 16.1 |
Ki67 | ||||||||
< 15 | 0/26 (100) | 1 | 0/25 (100) | 1 | ||||
≥ 15 | 5/34 (82) | 0.040 | – | – | 4/24 (83) | 0.014 | a | a |
Ki67 | ||||||||
< 30 | 1/38 (97) | 1 | 1/37 (95) | 1 | ||||
≥ 30 | 4/22 (82) | 0.033 | 7.5 | 0.84 to 67.5 | 3/12 (75) | 0.023 | 9.9 | 1.03 to 95.3 |
TILs | ||||||||
Negative | 4/55 (93) | 1 | 3/45 (93) | 1 | ||||
Positive | 1/6 (83) | 0.479 | 2.16 | 0.24 to 19.4 | 1/4 (75) | 0.24 | 3.6 | 0.37 to 34.6 |
Luminal statusc | ||||||||
Luminal A | 3/39 (92) | 1 | 2/28 (93) | 1 | ||||
Luminal B | 2/22 (91) | 0.847 | 1.2 | 0.20 to 7.41 | 2/22 (91) | 0.777 | 1.33 | 0.19 to 9.42 |
Chemo therapy | ||||||||
Yes | 5/39 (87) | 1 | 3/20 (85) | 1 | ||||
No | 0/22 (100) | 0.089 | 0.22 | 0.024 to 1.95 | 1/30 (97) | 0.15 | 0.22 | 0.023 to 2.10 |
Radiation therapy | ||||||||
Yes | 3/43 (93) | 1 | 2/38 (95) | 1 | ||||
No | 2/17 (88) | 0.499 | 1.84 | 0.33 to 11.0 | 2/12 (83) | 0.19 | 3.9 | 0.48 to 24.1 |
Endocrine therapy | ||||||||
Yes | 5/39 (87) | 1 | 4/36 (89) | 1 | ||||
No | 0/22 (100) | 0.089 | 0.024 | 0 to 46.4 | 0/14 (100) | 0.20 | 0.03 | 0 to 262 |
BMI-25d | ||||||||
< 25 | 1/31 (97) | 1 | 1/26 (96) | 1 | ||||
≥ 25 | 3/23 (87) | 0.177 | 4.19 | 0.44 to 40.3 | 2/20 (90) | 0.398 | 2.70 | 0.25 to 29.8 |
BMI-75pe | ||||||||
< 75p | 2/41 (95) | 1 | 2/36 (94) | 1 | ||||
≥ 75p | 2/13 (85) | 0.218 | 3.20 | 0.45 to 22.8 | 1/10 (90) | 0.622 | 1.81 | 0.16 to 20.0 |
Smoking | ||||||||
-Never smoked | 3/15 (80) | 1 | 2/12 (83) | 1 | ||||
-Former smoker | 0/23 (100) | 0.003 | Inf. | 0/20 (100) | 0.003 | Inf. | ||
-Ongoing smoking | 0/14 (100) | 0.020 | 0.003 | Inf | 0/12 (100) | 0.052 | 0.003 | Inf. |